AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 45 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $962,308 | -68.8% | 93,428 | -50.0% | 0.00% | -33.3% |
Q2 2023 | $3,082,090 | +17.6% | 187,020 | -34.6% | 0.00% | 0.0% |
Q1 2023 | $2,621,318 | +163.4% | 286,170 | +105.9% | 0.00% | 0.0% |
Q4 2022 | $995,276 | +24.9% | 139,005 | -12.6% | 0.00% | +50.0% |
Q3 2022 | $797,000 | +97.8% | 159,005 | -3.6% | 0.00% | +100.0% |
Q2 2022 | $403,000 | -44.3% | 165,005 | +55.6% | 0.00% | -50.0% |
Q1 2022 | $724,000 | -45.8% | 106,071 | -35.9% | 0.00% | -33.3% |
Q4 2021 | $1,336,000 | -17.5% | 165,355 | 0.0% | 0.00% | -25.0% |
Q3 2021 | $1,620,000 | +45.7% | 165,355 | 0.0% | 0.00% | +33.3% |
Q2 2021 | $1,112,000 | -25.6% | 165,355 | 0.0% | 0.00% | -25.0% |
Q1 2021 | $1,495,000 | +244.5% | 165,355 | +154.4% | 0.00% | +300.0% |
Q4 2020 | $434,000 | +32.3% | 65,005 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $328,000 | -71.1% | 65,005 | -56.7% | 0.00% | -75.0% |
Q4 2019 | $1,133,000 | +81.6% | 150,000 | 0.0% | 0.00% | +100.0% |
Q3 2019 | $624,000 | +43.8% | 150,000 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $434,000 | – | 150,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 4,133,464 | $45,592,000 | 5.54% |
Stonepine Capital Management, LLC | 747,863 | $8,249,000 | 4.45% |
JW Asset Management, LLC | 444,439 | $4,902,000 | 3.12% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $40,320,000 | 2.15% |
ARMISTICE CAPITAL, LLC | 1,150,000 | $12,685,000 | 1.62% |
FALCON POINT CAPITAL, LLC | 855,101 | $9,432,000 | 1.27% |
Perceptive Advisors | 1,429,114 | $15,763,000 | 0.79% |
KNOTT DAVID M | 126,463 | $1,395,000 | 0.58% |
HEARTLAND ADVISORS INC | 700,000 | $7,721,000 | 0.50% |
Sio Capital Management, LLC | 91,413 | $1,008,000 | 0.48% |